A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Cystic Fibrosis
- Sponsor
- Syntara
- Locations
- 8
- Primary Endpoint
- FEV1
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
Cystic fibrosis is the most frequent lethal genetic disease of childhood. Causes disruption of glandular function of the pancreas, intestine, liver, lungs (causing chronic lung infection with emphysema), sweat glands and reproductive organs. We know that many CF patients die of lung failure, brought about in part by repeated lung infections caused by thick, sticky mucus that cannot be readily cleared from the lung.
Inhaled mannitol is an osmotic agent that has been investigated in a number of small studies that have examined mucociliary clearance, quality of life and lung function in CF and bronchiectasis. The promising results of these studies warrant futher investigation. The aim of this study is to assess the safety and efficacy of inhaled mannitol when administered twice a day over two weeks in CF.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Confirmed diagnosis of cystic fibrosis (sweat test/genotype)
- •Aged 8 years or older
- •Have FEV1 between 40% and 80% of predicted for height, age and gender OR a decrease in FEV1 of 20% or more than that recorded 6-12 months previously.
- •As determined by the investigator, are capable and willing to
- •Use the study diary as required for this protocol
- •Able to perform all of the techniques necessary to measure lung function
- •Able to administer the dry powder mannitol
- •Are capable of and have given informed consent
- •Clinically stable at study entry
Exclusion Criteria
- •Investigators, site personnel directly affiliated with this study, and their immediate families.
- •Subjects under the age of 8 years.
- •Subjects with currently active asthma
- •Subjects using hypertonic saline treatment in the last 2 weeks
- •Considered "terminally ill" or listed for transplantation
- •Requiring home oxygen or assisted ventilation
- •Colonisation with Burkholderia cepacia
- •Significant episode of hemoptysis (\>60 mls) in the previous 12 months
- •Myocardial Infarction in the six months prior to enrolment.
- •Cerebral Vascular Accident in the six months prior to enrolment.
Outcomes
Primary Outcomes
FEV1
Secondary Outcomes
- Other measures of lung function
- Quality of life
- Sputum microbiology
- Sputum rheology
- Safety